Endoscopy
DOI: 10.1055/a-2788-2255
Innovations and brief communications

Feasibility and safety of endoscopic ultrasound-guided gallbladder drainage for Niemeier type II acute perforated cholecystitis: a multicenter retrospective pilot study

Authors

  • Hyung Ku Chon

    1   Division of Biliopancreas, Department of Internal Medicine, Wonkwang University College of Medicine, Institute of Wonkwang Medical Science, Iksan, Korea (the Republic of)
  • Eui Joo Kim

    2   Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea (the Republic of)
  • Se Woo Park

    3   Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si, Korea (the Republic of)
  • Yun Nah Lee

    4   Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon, Korea (the Republic of)
  • Seong-Hun Kim

    5   Division of Gastroenterology, Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea (the Republic of)

Supported by: Wonkwang University 2026 2026


Graphical Abstract

Abstract

Background

Acute perforated cholecystitis (APC) requires timely intervention, and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has emerged as a minimally invasive option for high-risk surgical candidates. This multicenter study evaluated the feasibility and safety of EUS-GBD in patients with Niemeier type II APC.

Methods

Patients with type II APC who underwent EUS-GBD between January 2017 and December 2024 at five tertiary centers were retrospectively analyzed. The primary outcome was technical success; secondary outcomes included clinical success, adverse events, stent patency, and 30- and 90-day all-cause mortality.

Results

22 patients with radiologically confirmed type II APC were included. Technical and clinical success were achieved in all patients. Three adverse events occurred: biloma, stent migration, and stent occlusion with recurrent acute cholecystitis. No 30-day mortality occurred; one patient died from pneumonia within 90 days. During a median follow-up of 350 days (interquartile range [IQR] 240–448), Kaplan–Meier stent patency remained at 90.9% and the median patency time was 327 days (IQR 203–413).

Conclusions

EUS-GBD appeared feasible and safe for high-risk patients with type II APC, achieving high technical and clinical success with a low rate of adverse events.



Publication History

Received: 19 August 2025

Accepted after revision: 13 January 2026

Article published online:
17 February 2026

© 2026. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany